EIF2AK3 and Parkinson disease: Enhanced PKR activation has been observed in patients and mouse models of AD, PD, and HD [38,39,40,41,42,43,44,45], and the inhibition of PERK, PKR, and GCN2 via genetic and pharmacologic means have shown beneficial effects [46,47,48,49].